现在在欧美等多个国家短时间内，BA.4/5感染者在疯狂上升，在德国等多个国家已经成为了主流毒株。而伴随的是BA.4/5的更强的逃逸性，使得BA.1/2的抗体大打折扣。当然这里也包含这Evusheld，已经有多项实验说明Evusheld对BA.4/5的效果打折扣了。
估计是碍于药厂的名声，大家用的语句还在用委婉的“似乎效果不佳”来形容Evusheld对BA.4/5的效力。
“In the study above, Evusheld didn’t appear to work very well against BA.4 or BA.5 and so this is something that we will need to keep an eye on.”
牛津大学也为阿斯利康的Evusheld紧急上线了一篇预印论文，说明Evusheld对BA.4/5保留了中和能力。当然阿斯利康也是第一时间发布了这一消息，之后也被反复的提起。
It is clear that the Omicron lineage, and particularly BA.4/5, has escaped or reduced the activity of mAbs developed for clinical use, although ADZ7442 and S309 still show activity against BA.4/5. New monoclonals and combinations may be needed to plug the gap in activity, to protect the extremely vulnerable and those unable to mount adequate vaccine responses.
很明显，Omicron系，特别是BA.4/5，已经逃避或降低了为临床使用而开发的mAbs的活性，尽管ADZ7442和S309对BA.4/5仍有活性。可能需要新的单克隆抗体和组合来填补活性方面的空白，以保护那些极其脆弱和无法产生足够疫苗反应的人。
The duration of protection provided by Evusheld against symptomatic SARS-CoV-2 infection may not be as long as was shown in the clinical trial supporting the initial authorization because the clinical trial data came from a time period before the emergence of the BA.1 and BA.1.1 subvariants. However, it is not known whether BA.1 and BA1.1 will still be circulating in the coming months or whether another Omicron subvariant, BA.2, for which Evusheld is expected to have greater neutralizing activity, will become dominant.
Evusheld对有症状的SARS-CoV-2感染的保护期可能没有支持最初授权的临床试验所显示的那么长，因为临床试验数据来自BA.1和BA.1.1亚变体出现之前的时期。然而，目前还不知道BA.1和BA1.1在未来几个月是否仍在流通，或者另一个Omicron亚变体BA.2（Evusheld预计对其具有更大的中和活性）是否会成为主导。
窥视卡
雷达卡
提升卡
置顶卡
沉默卡
喧嚣卡
变色卡
千斤顶
照妖镜
